Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

Munshi et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69dff1b61827a1d0b125552b — DOI: https://doi.org/10.1001/jamaoncol.2016.3160

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma· 2012 · 82 citations
2. Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)· 2014 · 6 citations
3. Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment· 2011 · 59 citations
4. Minimal residual disease in multiple myeloma: bringing the bench to the bedside· 2015 · 114 citations
5. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction· 2015 · 181 citations